Rab11 family interacting proteins as regulators of T cell recognition and infiltration in triple negative breast cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This ...

Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response? The following represents disclosure information provided by authors of this manuscript.

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems? The following represents disclosure information provided by authors of this manuscript. All relationships ...

My NIH-funded research has been accepted by JCO Journals. Now what? If your article is Open Access: JCO Journals will deposit all open access articles to PubMed Central on behalf of the authors. If ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Preoperative axillary US and MRI in early-stage breast cancer: Potential to prevent unnecessary axillary surgery. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

Breast cancer during pregnancy is uncommon; however, it is one of the most common malignancies affecting pregnant women. Pregnancy-associated breast cancer (PABC) is a complex entity characterized by ...

Quality improvement scorecards driving innovation and best practice in a large community oncology practice.

The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma. This is an ASCO Meeting Abstract from ...

PATIENTS AND METHODS: All patients undergoing radical cystectomy with bilateral pelvic iliac lymphadenectomy, with the intent to cure, for transitional-cell carcinoma of the bladder between July 1971 ...

KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested ...